BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Buy" Rating at Needham & Company LLC

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)'s stock had its "buy" rating reiterated by analysts at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports. They currently have a $17.00 price target on the biotechnology company's stock. Needham & Company LLC's price objective would indicate a potential upside of 81.62% from the stock's current price.

BCRX has been the subject of a number of other research reports. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target on the stock. Royal Bank Of Canada reissued an "outperform" rating and set a $13.00 price objective (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an "outperform" rating and a $15.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded down $0.30 during trading on Wednesday, reaching $9.36. The company's stock had a trading volume of 7,449,089 shares, compared to its average volume of 3,040,381. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -36.00, a P/E/G ratio of 2.19 and a beta of 1.11. The stock's 50-day moving average price is $9.96 and its 200 day moving average price is $8.55. BioCryst Pharmaceuticals has a 1-year low of $6.02 and a 1-year high of $11.31.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of BCRX. Lazard Asset Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 68.1% during the 4th quarter. Lazard Asset Management LLC now owns 161,516 shares of the biotechnology company's stock worth $1,214,000 after buying an additional 65,420 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after buying an additional 1,583,826 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $80,000. Teacher Retirement System of Texas lifted its position in shares of BioCryst Pharmaceuticals by 25.1% during the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company's stock worth $438,000 after buying an additional 11,711 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of BioCryst Pharmaceuticals by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after buying an additional 91,998 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.